Latest Conference Articles

Jonathan Silverberg, MD, PhD, MPH, presented late-breaking dupilumab data at RAD 2023.

Gooderham’s sessions covered upcoming AD drug approvals, patient satisfaction and QoL improvement, and RAD 2023 takeaways.

In a cohort of Chinese and Japanese pediatric patients, researchers deemed the topical treatment both safe and effective.

Raj Chovatiya, MD, PhD, discusses highlights from his sessions at RAD 2023 on best practices for AD management.

In 3 phase 3 clinical trials, the drug demonstrated significant improvements of AD when compared to a placebo.

Brett King, MD, PhD, gave an in-depth overview of how JAK inhibitors earned a boxed warning and what it means for treating patients with atopic dermatitis at RAD 2023.

In a diverse, urban cohort, researchers did not find discrepancies between disease severity or prescribed treatment.

De Benedetto shares her expertise on new discoveries in the science of atopic dermatitis at RAD 2023.

Catch up on coverage from the second day of Revolutionizing Atopic Dermatitis.

Jonathan Silverberg, MD, PhD, MPH, shares highlights and key takeaways from his RAD 2023 sessions.

Andrew Blauvelt, MD, MBA, discusses his RAD 2023 session, "Biologics for atopic dermatitis."

Andrew Blauvelt, MD, MBA, shares highlights from his RAD session, "Battle of the Titans 2: Challenging Patient Cases: Who is Eligible for Systemic Treatment in Atopic Dermatitis?"

A recently presented poster session from RAD 2023 evaluated a gene expression based molecular test’s differential diagnosis of psoriasis and eczema.

Among numerous sessions to be held this weekend at the Revolutionizing Atopic Dermatitis Conference in Washington, DC, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.

Catch up on coverage from the first day of Revolutionizing Atopic Dermatitis.

Revolutionizing Atopic Dermatitis Conference Chair Jonathan Silverberg, MD, PhD, MPH, previews this weekend's conference in Washington, DC.

The RAD conference provides the chance to take a deep dive into one specific disease state in a focused setting.

When sessions, late-breaking research, and more concludes, there is no shortage of things to do in the nation’s capital.

The 5th annual RAD conference kicks off April 29, 2023, in Washington, DC.

Let us know what content you want to see from RAD.

Click here to answer this week's poll.

Checkpoint inhibitors such as pembrolizumab nivolumab are playing a major role in cancer treatment, but they can also produce adverse events that affect the skin.

From acne and psoriasis to skin cancer and hair loss, leaders in the industry share their quick tips that help save time.

When a patient complains of breast pain, there are several special considerations for diagnosis and treatment.

Check out new, trending, and up-and-coming perspectives on the use of laser therapies in several dermatologic conditions.

Late-breaking positive phase 2a results were presented at AAD 2023.

Click here to answer this week's poll.

More than 300 innovative sessions, an engaging exhibit hall, and heartfelt networking—there was a lot to pack into AAD 2023! Here are the highlights.